Beckman Coulter Shares Drop on Troponin Test Issues | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Shares of Beckman Coulter fell around 7 percent in early Tuesday afternoon trade after the firm disclosed that it will likely have to impose further restrictions on the use of its troponin test kits after discussions with the US Food and Drug Administration.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.